BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 922 filers reported holding BAXTER INTL INC in Q1 2024. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $333,329 | -77.0% | 9,965 | -70.6% | 0.06% | -79.1% |
| Q1 2024 | $1,446,322 | -46.0% | 33,840 | -51.1% | 0.29% | -46.4% |
| Q4 2023 | $2,676,200 | +280.5% | 69,224 | +271.5% | 0.54% | +283.8% |
| Q3 2023 | $703,323 | -30.4% | 18,636 | -15.9% | 0.14% | -18.9% |
| Q2 2023 | $1,009,837 | -20.2% | 22,165 | -29.0% | 0.18% | +5.4% |
| Q1 2023 | $1,265,472 | +254.7% | 31,200 | +345.7% | 0.17% | +435.5% |
| Q4 2022 | $356,790 | -89.1% | 7,000 | -88.4% | 0.03% | -84.0% |
| Q3 2022 | $3,264,000 | +35.3% | 60,600 | +61.3% | 0.19% | +110.9% |
| Q2 2022 | $2,413,000 | +223.0% | 37,563 | +304.8% | 0.09% | +253.8% |
| Q2 2021 | $747,000 | +177.7% | 9,279 | +190.4% | 0.03% | +62.5% |
| Q1 2021 | $269,000 | -71.8% | 3,195 | -73.1% | 0.02% | -80.2% |
| Q3 2020 | $955,000 | +23.5% | 11,878 | +32.3% | 0.08% | +6.6% |
| Q2 2020 | $773,000 | -57.2% | 8,978 | -58.4% | 0.08% | -16.5% |
| Q4 2019 | $1,806,000 | +179.1% | 21,600 | +119.8% | 0.09% | -38.9% |
| Q4 2018 | $647,000 | -40.1% | 9,829 | -29.9% | 0.15% | -63.1% |
| Q3 2018 | $1,081,000 | -64.3% | 14,029 | -65.8% | 0.40% | -60.6% |
| Q2 2018 | $3,030,000 | +83.2% | 41,029 | +61.3% | 1.02% | +84.0% |
| Q1 2018 | $1,654,000 | -44.8% | 25,429 | -45.1% | 0.56% | -35.7% |
| Q4 2017 | $2,995,000 | +454.6% | 46,329 | +438.1% | 0.87% | +392.0% |
| Q3 2017 | $540,000 | -31.5% | 8,609 | -33.8% | 0.18% | -17.8% |
| Q2 2017 | $788,000 | – | 13,009 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
| NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
| Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
| Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
| GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
| Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
| Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
| Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
| Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |